After 6 months of therapy, those taking GLP1 drugs showed: Elevated risk of androgenic alopecia Elevated risk of nonscarring hair loss No significant change in telogen effluvium risk No significant change in alopecia areata risk At the 12-month mark, the pattern had shifted slightly: Continued higher risk for androgenic alopecia Continued higher risk for nonscarring hair loss A newly increased risk of telogen effluvium Still no change in risk of alopecia areata The apparent absence of a link between GLP1 medications and alopecia areata is especially notable, as isolated case reports have previously suggested an association
Interleukin-1 blockade with RPH-104 (Goflikicept) in patients with ST-segment elevation myocardial infarction: secondary end points from an international, double-blind, randomized, placebo-controlled, phase 2a study
Our B12 injection services are particularly beneficial for clients with specific medical conditions, such as pernicious anemia, gastrointestinal disorders (like Crohns disease or celiac disease), or those who have undergone surgeries that impact nutrient absorption, such as gastric bypass
[DOI] [PMC free article] [PubMed] [Google Scholar] (501).Karagiannis ED